These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 32040755)
1. [Reality of inpatient vasoactive treatment with prostacyclin derivatives in patients with acral circulation disorders due to systemic sclerosis in Germany]. Juche A; Siegert E; Mueller-Ladner U; Riemekasten G; Günther C; Kötter I; Henes J; Blank N; Voll RE; Ehrchen J; Schmalzing M; Susok L; Schmeiser T; Sunderkoetter C; Distler J; Worm M; Kreuter A; Horváth ON; Schön MP; Korsten P; Zeidler G; Pfeiffer C; Krieg T; Hunzelmann N; Moinzadeh P Z Rheumatol; 2020 Dec; 79(10):1057-1066. PubMed ID: 32040755 [TBL] [Abstract][Full Text] [Related]
2. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170 [TBL] [Abstract][Full Text] [Related]
3. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma. Colakoğlu M; Cobankara V; Akpolat T Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574 [TBL] [Abstract][Full Text] [Related]
4. [Treatment of Raynaud's phenomenon in scleroderma with a new stable prostacyclin derivative]. Keller J; Kaltenecker A; Schricker KT; Krais T; Schönberger A; Gevatter M; Hornstein OP Dtsch Med Wochenschr; 1984 Sep; 109(38):1433-8. PubMed ID: 6383760 [TBL] [Abstract][Full Text] [Related]
5. Management of cutaneous vascular complications in systemic scleroderma: experience from the German network. Herrgott I; Riemekasten G; Hunzelmann N; Sunderkötter C Rheumatol Int; 2008 Aug; 28(10):1023-9. PubMed ID: 18320192 [TBL] [Abstract][Full Text] [Related]
6. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711 [TBL] [Abstract][Full Text] [Related]
7. Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis. McHugh NJ; Csuka M; Watson H; Belcher G; Amadi A; Ring EF; Black CM; Maddison PJ Ann Rheum Dis; 1988 Jan; 47(1):43-7. PubMed ID: 2449871 [TBL] [Abstract][Full Text] [Related]
8. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis]. Serri J; Legré R; Veit V; Guardia C; Gay AM Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894 [TBL] [Abstract][Full Text] [Related]
9. Vascular biomarkers and digital ulcerations in systemic sclerosis: results from a randomized controlled trial of oral treprostinil (DISTOL-1). Mecoli CA; Perin J; Van Eyk JE; Zhu J; Fu Q; Allmon AG; Rao Y; Zeger S; Wigley FM; Hummers LK; Shah AA Clin Rheumatol; 2020 Apr; 39(4):1199-1205. PubMed ID: 31858338 [TBL] [Abstract][Full Text] [Related]
10. Prolonged increase in digital blood flow following iloprost infusion in patients with systemic sclerosis. Rademaker M; Thomas RH; Provost G; Beacham JA; Cooke ED; Kirby JD Postgrad Med J; 1987 Aug; 63(742):617-20. PubMed ID: 2447572 [TBL] [Abstract][Full Text] [Related]
11. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Pope J; Fenlon D; Thompson A; Shea B; Furst D; Wells G; Silman A Cochrane Database Syst Rev; 2000; 1998(2):CD000953. PubMed ID: 10796395 [TBL] [Abstract][Full Text] [Related]
12. [Efficacy of beraprost sodium on Raynaud's phenomenon in patients with systemic sclerosis]. Kaburaki J; Kuwana M; Akizuki M; Takano M; Tojo T Nihon Rinsho Meneki Gakkai Kaishi; 1995 Feb; 18(1):29-35. PubMed ID: 7553036 [TBL] [Abstract][Full Text] [Related]
13. [Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis]. Cordioli E; Virgilio S; Ghirardi R; Martinelli M Minerva Med; 1992 Nov; 83(11):739-44. PubMed ID: 1281297 [TBL] [Abstract][Full Text] [Related]
14. Treatment of complications associated with systemic sclerosis. Moore SC; Desantis ER Am J Health Syst Pharm; 2008 Feb; 65(4):315-21. PubMed ID: 18238768 [TBL] [Abstract][Full Text] [Related]
15. [Iloprost for the treatment of systemic sclerosis]. Hachulla E; Launay D; Hatron PY Presse Med; 2008 May; 37(5 Pt 2):831-9. PubMed ID: 18035518 [TBL] [Abstract][Full Text] [Related]
16. Is iloprost effective in secondary Raynaud's phenomenon? Lustig N; Rada G Medwave; 2015 Mar; 15(2):e6082. PubMed ID: 25826330 [TBL] [Abstract][Full Text] [Related]
17. A randomised, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud's phenomenon secondary to systemic sclerosis. Lau CS; Belch JJ; Madhok R; Cappell H; Herrick A; Jayson M; Thompson JM Clin Exp Rheumatol; 1993; 11(1):35-40. PubMed ID: 8453795 [TBL] [Abstract][Full Text] [Related]